CeriBell (CBLL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.40
- Estimate
- -$0.46
- Surprise
- +11.9%
- Revenue (period 2026-06-30)
- $28.1M
- Score today
- 5.7/10
Revenue source: xbrl.
How the report landed
CeriBell (CBLL) reported a narrower loss than forecast — adjusted EPS of -$0.40 against the -$0.46 estimate (a 11.9% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CBLL Sell at 5.7/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +11.9% surprise compares with a +8.4% four-quarter average. Next scheduled report: 2027-02-23.
What argues against it
- Concentration risk — Product: Ceribell System
- Concentration risk — Geographic: United States sales (100.0%)
- Quality below floor (3.2 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $26.42
- Price target
- $27.47
- Stop
- $24.57
- Upside to target
- +4.0%
- Reward-to-risk
- 0.3:1
Model outputs from TrendMatrix’s engine as of 2026-11-17 — shown for context, not personalized investment advice.
CBLL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.02B
- P/E (fwd)
- -15.3
- 52-week range
- $12.65–$28.89
- Off 52-week high
- 8.5%
- RSI (14)
- 46
- Volume vs avg
- 1.30×
- Score today
- 5.7/10